New York, January 5, 2026, 15:35 EST — Regular session
Merck & Co (NYSE:MRK) shares edged up on Monday as investors looked ahead to the drugmaker’s appearance at the annual J.P. Morgan Healthcare Conference next week. The stock was up 0.3% at $106.80 at 3:35 p.m. EST, after earlier reaching $108.30.
The conference is a closely watched early-year marker for healthcare stocks, often offering the first public read on management priorities before earnings season ramps up.
Merck’s share performance has also been tied to investor confidence in its longer-term growth story, led by the cancer immunotherapy Keytruda and a broader pipeline of newer medicines and vaccines.
Merck said Chief Executive Robert M. Davis and Merck Research Laboratories chief Dean Y. Li will take part in a “fireside chat” — an onstage interview — on Jan. 12, and the company will webcast the session. Merck
The stock’s slight gain came as the Health Care Select Sector SPDR Fund slipped 0.4% in afternoon trade. Pfizer was down 0.1%, Johnson & Johnson fell 1.8% and Eli Lilly slid 3.5%.
Merck traded between $105.29 and $108.30 on Monday, after opening at $107.01, according to LSEG data. On charts, traders will be watching whether the stock can hold above the $105 area, while the $108 level is the near-term hurdle after Monday’s test.
Beyond next week’s conference, attention is shifting to earnings and any updates on Merck’s 2026 priorities, including how it intends to defend growth as competition builds across big categories and as biosimilars — near-copy versions of biologic drugs — loom for some older products.
But investors may get limited incremental news from the conference slot, leaving the stock more exposed to broader market swings in the near term. Any downbeat tone on demand trends or spending could also put pressure on expectations ahead of results.
Merck is scheduled to speak at the J.P. Morgan Healthcare Conference on Jan. 12 and to hold its fourth-quarter earnings call on Feb. 3, according to the company’s investor events calendar.
